Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosgonimeton in mild to moderate Alzheimer's disease
NCT04488419Phase 3Completed
- Sponsor
- LeonaBio
- Start
- Sep 2020
- Primary completion
- Jul 2024
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of fosgonimeton in Alzheimer's disease (AD), sponsored by LeonaBio. Started Sep 2020; status: completed.
02
Drugs
fosgonimeton
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04488419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04488419.